Les troubles cognitifs et psychiatriques liés à la consommation de cannabis Alain DERVAUX, Marie-Odile KREBS , Xavier LAQUEILLE Bulletin de l'Académie Nationale de Médecine, 2014, 198, no 3, 559-577, séance du 25 mars 2014 RÉSUMÉ Plusieurs études ont montré que le Δ-9-THC, principal principe actif du cannabis entraînait des troubles de l’attention, de la mémoire et des fonctions exécutives. Ils sont liés à la dose, à la fréquence, à la durée d’exposition et à l’âge de la première consommation. Ils peuvent disparaître après sevrage, mais des anomalies durables s’observent chez les sujets ayant débuté leur consommation avant l’âge de 15 ans. La fréquence de [...]
Lire la suite6 variétés de cannabis pleines de THCV Aurélien BERNARD Newsweed.fr, 30 janvier 2020 https://www.newsweed.fr/5-varietes-cannabis-thcv/ À mesure que les connaissances scientifiques sur le cannabis se développent, la composition chimique du cannabis et la manière dont il interagit avec le corps se dévoilent. Et si le CBD ou le THC sont largement étudiés, certains cannabinoïdes plus rares comme le THCV (tetrahydocannabivarine) intéressent de plus en plus les scientifiques. Au cours de la dernière décennie, des études sur des humains et des animaux ont identifié le potentiel du THCV pour réduire l’appétit chez les personnes qui luttent pour perdre du poids, réguler la glycémie chez les personnes atteintes [...]
Lire la suiteMedicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8 Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]
Lire la suiteCannabis for Sleep: Short-Term Benefit, Long-Term Disruption ? Michael Vlessides Medscape, January 24, 2020 https://www.medscape.com/viewarticle/924202_print Patients suffering from chronic pain who take medicinal cannabis to initiate and maintain sleep appear to experience short-term benefit, but long-term use may ultimately disrupt slumber, new research shows. Investigators found whole-plant medical cannabis use was associated with fewer problems with respect to waking up at night, but they also found that frequent medical cannabis use was associated with more problems initiating and maintaining sleep. "Cannabis may improve overall sleep in the short term," study investigator Sharon Sznitman, PhD, University of Haifa Faculty of Social Welfare and Health Sciences in Israel, [...]
Lire la suiteRisk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation Among Adolescents Jessica L. Barrington-Trimis, PhD; Junhan Cho, PhD; Esthelle Ewusi-Boisvert, BA; Deborah Hasin, PhD; Jennifer B. Unger, PhD; Richard A. Miech, PhD; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (1), e1919792. doi : 10.1001/jamanetworkopen.2019.19792 Abstract IMPORTANCE : While a diverse array of cannabis products that may appeal to youth is currently available, it is unknown whether the risk of persistent cannabis use and progression to higher frequency of use after experimentation differs among cannabis products. OBJECTIVE : To estimate the comparative relative risk of experimental use of 5 cannabis products [...]
Lire la suiteThe health and social effects of nonmedical cannabis use World Health Organization, 2016. CONTENTS Foreward. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . v Acknowledgements .. . . . . . . . . . . . . . . . . . . [...]
Lire la suiteAssociation Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016 Magdalena Cerdá, DrPH; Christine Mauro, PhD; Ava Hamilton, BA; Natalie S. Levy, MPH; Julián Santaella-Tenorio, DrPH; Deborah Hasin, PhD; Melanie M.Wall, PhD; Katherine M. Keyes, PhD; Silvia S. Martins, MD, PhD JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.3254 IMPORTANCE : Little is known about changes in marijuana use and cannabis use disorder (CUD) after recreational marijuana legalization (RML). OBJECTIVES : To examine the associations between RML enactment and changes in marijuana use, frequent use, and CUD in the United States from 2008 to 2016. DESIGN, SETTING, AND [...]
Lire la suiteAntidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression Eun-Sang Hwang, Hyun-Bum Kim, Seok Lee, Min-Jeong Kim, Kwan-Joong Kim, Gaeul Han, Se-Young Han, Eun-A Lee, Jeong-Hee Yoon, Dae-Ok Kim, Sungho Maeng, Ji-Ho Park Behavioural Brain Research, 2020, 380, 112439 doi : 10.1016/j.bbr.2019.112439 A B S T R A C T Chronic stress is depressogenic by altering neurotrophic and neuroinflammatory environments of the organism. The endocannabinoid system controls cognitive and emotional responses related with stress through the interaction with endocannabinoid receptors. β-Caryophyllene (BCP) is a CB2 agonist that exhibited anti-inflammatory, analgesic effects but minimal psychoactive effects. To test if BCP exhibits antidepressant-like action, animals were chronically restrained with additional [...]
Lire la suiteProlonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094 The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]
Lire la suiteA behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Leonora E. Long, Rose Chesworth, Xu-Feng Huang, Iain S. McGregor, Jonathon C. Arnold and Tim Karl International Journal of Neuropsychopharmacology, 2010, 13, 861–876. doi : 10.1017/S1461145709990605 Abstract Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9 tetrahydro-cannabinol (D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, [...]
Lire la suite